Ibrutinib also reduces expression of inhibitory receptors such as PD-1 and restores immune synapse formation between T cells and CLL cells such as decreased production of IL-10 or downregulation of inhibitory molecules like PD-L1 [57]. This evidence concerns the gene CD274 and B-cell chronic lymphocytic leukemia.